Attached files

file filename
EX-32.2 - EXHIBIT 32.2 - Universal Resourcesv328258_ex32-2.htm
EXCEL - IDEA: XBRL DOCUMENT - Universal ResourcesFinancial_Report.xls
10-K - FORM 10-K - Universal Resourcesv328258_10k.htm
XML - IDEA: XBRL DOCUMENT - Universal ResourcesR5.htm
XML - IDEA: XBRL DOCUMENT - Universal ResourcesR2.htm
XML - IDEA: XBRL DOCUMENT - Universal ResourcesR3.htm
XML - IDEA: XBRL DOCUMENT - Universal ResourcesR4.htm
XML - IDEA: XBRL DOCUMENT - Universal ResourcesR7.htm
XML - IDEA: XBRL DOCUMENT - Universal ResourcesR6.htm
XML - IDEA: XBRL DOCUMENT - Universal ResourcesR9.htm
XML - IDEA: XBRL DOCUMENT - Universal ResourcesR8.htm
XML - IDEA: XBRL DOCUMENT - Universal ResourcesR1.htm
XML - IDEA: XBRL DOCUMENT - Universal ResourcesR10.htm
XML - IDEA: XBRL DOCUMENT - Universal ResourcesR12.htm
XML - IDEA: XBRL DOCUMENT - Universal ResourcesR11.htm
EX-32.1 - EXHIBIT 32.1 - Universal Resourcesv328258_ex32-1.htm
EX-31.2 - EXHIBIT 31.2 - Universal Resourcesv328258_ex31-2.htm

 

Exhibit 31.1

 

Sarbanes-Oxley Act of 2002 CEO 302 CERTIFICATION PURSUANT TO RULE 13A-15(E)/15D-15(E)

 

Certification of the Chief Executive Officer

 

I, Serge Talon, certify that:

 

(1)I have reviewed this annual report on Form 10-K of Global Immune Technologies, Inc.

 

(2)Based on my knowledge, this Annual Report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this annual report;

 

(3)Based on my knowledge, the financial statements and other financial information included in this annual report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this annual report;

 

(4)The registrant’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15(d)-15(f) for the registrant and have:

 

(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its subsidiaries, if any, is made known to us by others within those entities, particularly during the period in which this annual report is being prepared;

 

(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;

 

(d)Disclosed in this report any changes in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

(5)The registrant’s other certifying officers and I have disclosed, based on our most recent evaluation of the internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions):

 

(a)all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

 

Date: October 31, 2012

  Global Immune Technologies, Inc.
   
  By: /s/ Serge Talon
      President & CEO